Development of an homologous recombination deficiency scoring algorithm for unmatched ovarian tumor sample based on next-generation sequencing
Open Access
- 1 January 2026
- journal article
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (5)
Abstract
Wang Z, et al. J Gynecol Oncol. 2026 ;37:e97. https://doi.org/10.3802/jgo.2026.37.e97Keywords
Funding Information
- Henan Province Key Science and Technology Program 2023 (232102311026)
- Major Science and Technology Projects of Henan (221100310100)
- Harbin Medical University Cancer Hospital (Nn102024-05)
- Heilongjiang Province Innovation Base Award Project (JD2023SJ03)
- Natural Science Foundation of Heilongjiang Province (LH2022H065)
- Fundamental Scientific funds for the Provincial Universities in Heilongjiang Province
This publication has 23 references indexed in Scilit:
- Improved detection of homologous recombination deficiency in Chinese patients with ovarian cancer: a novel non‐exonic single‐nucleotide polymorphism‐based next‐generation sequencing panelMolecular Oncology, 2023
- Olaparib for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2020
- Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerNew England Journal of Medicine, 2019
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialThe Lancet Oncology, 2019
- The International Cancer Genome Consortium Data PortalNature Biotechnology, 2019
- Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancernpj Breast Cancer, 2018
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Gynecologic Oncology, 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Sequenza: allele-specific copy number and mutation profiles from tumor sequencing dataAnnals of Oncology, 2014
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012